CRISPR Therapeutics AG (CRSP) Long-Term Debt Issuances (2016 - 2026)
CRISPR Therapeutics AG's (CRSP) quarterly Long-Term Debt Issuances came in at $600.0 million in Q1 2026, up 5999900.0% quarter-over-quarter from $10000.0 in Q4 2016.
Powered by 
Analysis
CRISPR Therapeutics AG (CRSP) Long-Term Debt Issuances (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has disclosed Long-Term Debt Issuances across 2 years of filings, most recently posting $600.0 million for Q1 2026.
- In Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $600.0 million; the TTM figure through Jun 2026 stood at $600.0 million (up 5999900.0% YoY), while the FY2016 annual figure was $35.0 million, down 8.44% from the prior year.
- Long-Term Debt Issuances came in at $600.0 million for Q1 2026 at CRISPR Therapeutics AG, up from $10000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $600.0 million in Q1 2026 to a low of $600.0 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 600.00 Mn |
| Dec 31, 2016 | 10,000.00 |
| Mar 31, 2016 | 35.00 Mn |